← Previous Post: | Next Post:

 

“The drug costs more than $23,000 a vial; Questcor, betting on its value, had raised the price from $1,650 a vial in 2007.”

America, America. Can’t say we don’t know how to make money. Especially off of dying people.

I mean, you know, suck it up. You’ve got kidney disease, and you’re going to die… So you’re going to shell out the $23,000 for that little vial. Aren’t you?

Which is going to make one particular university professor very happy. Columbia University’s Andrew Bomback, in what sounds like the same form of business relationship Chip Skowron cultivated, has been talking to rich hedgies about his medical research… and it all has that je ne sais quoi, insidery tradery, feel to it, according to the state of Massachusetts.

Mr. Silverman [the hedgie], after talking with Dr. Bomback on June 14, 2010, invested $846,889 in Questcor [the company with the little vials] between July 6 and Sept. 9, the Massachusetts filing showed. He paid an average of $9.80 a share. The stock closed Friday at $27.27 a share, giving him a paper gain of $1.5 million.

Margaret Soltan, September 17, 2011 2:10PM
Posted in: conflict of interest

Trackback URL for this post:
https://www.margaretsoltan.com/wp-trackback.php?p=32504

One Response to ““The drug costs more than $23,000 a vial; Questcor, betting on its value, had raised the price from $1,650 a vial in 2007.””

  1. adam Says:

    Gaming the system – that’s the new entitlement of academic entrepreneurs.

Comment on this Entry

Latest UD posts at IHE

Archives

Categories